Park K J, Yoon W H, Shin W G, Lee M G
College of Pharmacy, Seoul National University, Korea.
J Pharm Pharmacol. 1996 Oct;48(10):1093-7. doi: 10.1111/j.2042-7158.1996.tb05906.x.
Because physiological changes occurring in diabetes mellitus patients could alter the pharmacokinetics and pharmacodynamics of the drugs used to treat the disease, the pharmacokinetics and pharmacodynamics of azosemide were investigated after intravenous and oral administration of the drug (10 mg kg-1) to control and alloxan-induced diabetes mellitus rats (AIDRs). After intravenous administration of azosemide to the AIDRs, the area under the plasma concentration-time curve (AUC) increased considerably (3120 compared with 2520 micrograms min mL-1; P < 0.135) and the total body clearance decreased considerably (3.20 compared with 3.96 mL min-1 kg-1; P < 0.0593). The considerable reduction in time-averaged total body clearance in the AIDRs was a result of the significant decrease in renal clearance (1.01 compared with 1.55 mL min-1 kg-1) in the AIDRs, the non-renal clearance being comparable between the two groups of rats. After intravenous administration, the 8-h urinary excretion of azosemide (29.5 compared with 40% of intravenous dose; P < 0.0883) and one of its metabolites, M1 (2.15 compared with 2.60% of intravenous dose, expressed in terms of azosemide; P < 0.05) decreased in the AIDRs because of the impaired kidney function. The diuretic, natriuretic, kaliuretic and chloruretic efficiencies increased significantly in the AIDRs. After oral administration of azosemide, AUC decreased significantly in the AIDRs (115 compared with 215 micrograms min mL-1) possibly because of the reduced gastrointestinal absorption of azosemide in the AIDRs. After oral administration of azosemide, the 8-h urine output decreased significantly in the AIDRs (9.32 compared with 16.1 mL per 100 g body weight) because of the significantly reduced 8-h urinary excretion of azosemide (3.00 compared with 9.14% of oral dose). After both intravenous and oral administration some pharmacokinetic and pharmacodynamic parameters of azosemide were significantly different in AIDRs.
由于糖尿病患者发生的生理变化会改变用于治疗该疾病的药物的药代动力学和药效学,因此在给对照大鼠和四氧嘧啶诱导的糖尿病大鼠(AIDRs)静脉注射和口服阿佐塞米(10mg/kg)后,研究了其药代动力学和药效学。给AIDRs静脉注射阿佐塞米后,血浆浓度-时间曲线下面积(AUC)显著增加(分别为3120和2520μg·min/mL;P<0.135),全身清除率显著降低(分别为3.20和3.96mL·min-1·kg-1;P<0.0593)。AIDRs中时间平均全身清除率的显著降低是由于AIDRs中肾清除率显著降低(分别为1.01和1.55mL·min-1·kg-1),两组大鼠的非肾清除率相当。静脉注射后,由于肾功能受损,AIDRs中阿佐塞米的8小时尿排泄量(分别为静脉注射剂量的29.5%和40%;P<0.0883)及其代谢物之一M1(分别为静脉注射剂量的2.15%和2.60%,以阿佐塞米计;P<0.05)降低。AIDRs中的利尿、利钠、利钾和利氯效率显著增加。口服阿佐塞米后,AIDRs中的AUC显著降低(分别为115和215μg·min/mL),这可能是由于AIDRs中阿佐塞米的胃肠道吸收减少。口服阿佐塞米后,由于阿佐塞米的8小时尿排泄量显著降低(分别为口服剂量的3.00%和9.14%),AIDRs中的8小时尿量显著降低(分别为每100g体重9.32和16.1mL)。静脉注射和口服后,AIDRs中阿佐塞米的一些药代动力学和药效学参数存在显著差异。